Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
RESEARCH TOOLSreports
Holding GLUE?
Track your performance easily
GLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.44 - $8.84
Previous Close$5.95
Volume158.87K
Average Volume (3M)238.92K
Market Cap
$381.13M
Enterprise Value$147.32M
Total Cash (Recent Filing)$262.20M
Total Debt (Recent Filing)$44.36M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Nov 07, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares Outstanding61,372,824
10 Day Avg. Volume229,195
30 Day Avg. Volume238,921
Standard Deviation0.27
R-Squared0.07
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.63
Price to Sales (P/S)59.02
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.93
Enterprise Value/Gross Profit371.08
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$12.75Price Target Upside105.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Monte Rosa Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $2.44 and its highest was $8.84 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Currently, no data Available
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.091.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is -$0.47.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 61,372,826 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 10.249%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Among the largest hedge funds holding Monte Rosa Therapeutics’s share is Baker Bros Advisors LP. It holds Monte Rosa Therapeutics’s shares valued at 18M.
---
Monte Rosa Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (105.31% Upside)
$12.75 (105.31% Upside)
Hedge Fund Trend
Decreased
By 15.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.16%
12-Months-Change
Fundamentals
Return on Equity
-59.51%
Trailing 12-Months
Asset Growth
23.51%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
---
GLUE Stock 12 Month Forecast
Average Price Target
$12.75
▲(105.31% Upside)
Technical Analysis
Best Analysts Covering GLUE
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
+27.84%
assigned a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +27.84% per trade.
---